A detailed history of Squarepoint Ops LLC transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Squarepoint Ops LLC holds 115,105 shares of ZNTL stock, worth $370,638. This represents 0.0% of its overall portfolio holdings.

Number of Shares
115,105
Previous 148,755 22.62%
Holding current value
$370,638
Previous $608,000 30.59%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.9 - $4.57 $97,585 - $153,780
-33,650 Reduced 22.62%
115,105 $422,000
Q2 2024

Aug 14, 2024

BUY
$4.09 - $16.13 $513,904 - $2.03 Million
125,649 Added 543.79%
148,755 $608,000
Q1 2024

May 15, 2024

BUY
$10.83 - $16.49 $250,237 - $381,017
23,106 New
23,106 $364,000
Q2 2023

Aug 14, 2023

BUY
$17.41 - $30.05 $1.1 Million - $1.9 Million
63,218 Added 374.2%
80,112 $2.26 Million
Q1 2023

May 15, 2023

BUY
$16.14 - $24.94 $272,669 - $421,336
16,894 New
16,894 $290,000
Q3 2022

Nov 14, 2022

BUY
$20.23 - $31.73 $592,111 - $928,705
29,269 New
29,269 $634,000
Q2 2022

Aug 15, 2022

SELL
$17.91 - $52.25 $370,360 - $1.08 Million
-20,679 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$41.58 - $80.89 $669,063 - $1.3 Million
16,091 Added 350.72%
20,679 $954,000
Q4 2021

Feb 14, 2022

BUY
$66.92 - $84.79 $307,028 - $389,016
4,588 New
4,588 $386,000
Q3 2021

Nov 15, 2021

SELL
$46.83 - $73.5 $916,790 - $1.44 Million
-19,577 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$37.41 - $62.25 $732,375 - $1.22 Million
19,577 New
19,577 $1.04 Million
Q1 2021

May 17, 2021

SELL
$35.69 - $52.72 $386,344 - $570,694
-10,825 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$31.71 - $57.97 $343,260 - $627,525
10,825 New
10,825 $562,000

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $183M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.